Antimicrobial Copper

Economics and case studies

Medica, Dusseldorf 21st November 2013

Mark Tur, CDA Technical Consultant



Content

01.	00	Intro	odu	ction	&	context
-----	----	-------	-----	-------	---	---------

- 02.00 Clinical evidence and case studies
- 03.00 What about cost?
- 04.00 Conclusion and next steps



01.00 Introduction & context

Europe – some headline numbers

HCAIs... infections resulting from healthcare interventions

- 7.1% overall prevalence rate over 4.1 million patients affected
- Up to 51% prevalence in Intensive Care Units (ICUs)
- 16 million extra days in hospital
- Direct costs: €7 billion
- 37,000 deaths directly caused by HCAIs
- Additional 110,000 deaths where HCAIs contributory factor



02.00 Clinical evidence and case studies

Independent clinical trials have been conducted at multiple locations around the world



Fighting infections is a multifaceted challenge



- Antimicrobial Copper needs to be seen as a supplement to, not a substitute for, standard infection control practices.
- One must continue to follow all current practices, including those related to cleaning and disinfection of environmental surfaces.
- Antimicrobial Copper is compatible with hospital cleaning agents.
- Antimicrobial Copper alloy surfaces must not be waxed, painted, lacquered, varnished, or otherwise coated. The alloys oxidize to varying degrees, which does not impair their antimicrobial efficacy.

University Hospitals Birmingham, NHS Foundation Trust

Selly Oak clinical trial - UK







UHB, NHS Foundation Trust

Selly Oak clinical trial - UK





UHB, NHS Foundation Trust

Selly Oak clinical trial - UK





























Reinhard Tennert, Director of AKH:

"It is important for us to get ahead with investing in supplementary hygiene measures, and to therefore be able to offer our youngest patients the best possible protection against infections carried by germs.

Cases of illness resulting from a lack of hygiene are **unethical**, **extremely expensive** due to treatment costs of up to a quarter of a million Euros per case of treatment, and furthermore have a negative effect on the **image** of the whole organisation."



Craigavon Area Hospital, N. Ireland

Maternity and Surgery







Craigavon Area Hospital, N. Ireland

Maternity and Surgery







Homerton University Hospital, London, UK







Homerton University Hospital, London, UK









Roberto del Rio Children's Hospital, Chile

Paediatric Hospital







Roberto del Rio Children's Hospital, Chile

Paediatric Hospital





Roberto del Rio Children's Hospital, Chile

Dr Ignacio Hernandez, Director of Roberto del Rio:

"This initiative will benefit children who are hospitalised in critical conditions as they will be in a healthier environment."



03.00 What about cost?





An Economic Evaluation of the use of Copper in Reducing the Rate of Healthcare Associated Infections in the UK

Presented at:

- WHO International Infection Control Conference, Geneva (ICPIC 2013)
- The International Society for Pharmacoeconomics and Outcomes Research, Dublin (ISPOR 2013)

Providing Consultancy & Research in Health Economics








The Business Case for Copper

- YEHC Global leader in healthcare associated modelling
- Model developed to calculate payback for upgrading to copper
- Allows input of local HCAI rates and costs
- Works in £, € or \$
- Fully referenced model









Outcome and length of stay in different European and North American ICUs. Results from the European/North American scoring multicenter study in 137 ICUs with 13,152 intensive care patients (51)

Country	ICU Patients (n)	Mortality Rate (%)	Length of ICU Stay (days)	Length of Hospital Stay (days)***	Mean Score SAPS II	Mortality Observed/Expected
Belgium	1,091	21.7	6.2	21.5	0.9	1.12
Finland	720	17.6	4.1	14.0	31.0	0.88
France	1,393	28.9	9.7	18.9	40.5	0.92
Germany*	1,807	15.7	6.0	21.0**	30.3	0.9
Italy	1,297	31.3	7.2	20.5	38.6	1.07
Spain	1,270	27.1	9.5	22.8	32.2	1.31
Switzerland	756	13.8	4.9	17.6	30.7	0.74
The	950	20.0	5.5	19.3	31.3	1.02
Netherlands						
United	136	32.4	5.7	14.8	42.1	0.96
Kingdom						
U.S./Canada	3,732	19.7	5.9	17.1	32.1	0.96
Total	13,152	21.8	6.6	19.1	33.2	0.99


^{*} Including one ICU from Austria


^{***} No. of days in hospital from beginning of ICU stay





^{**} The average length of stay in German hospitals is about 14 days







Model Inputs



The following infection rates are taken from published papers. To change to hospital specific rates, the rate and the time period in should be entered into the appropriate cells and 'user defined data' should be selected in the drop down menu. A new monthly rate




^{*}Rates from Salgado (2013) showed a reduction of 58.1% for the copper arm versus non-copper arm. A conservative assumption





	Unit cost
Cost of an additional day in hospital due to infection	€ 1,000
Visit to general practitioner	€0
Outpatient	€0

Cost of equipment					
	Unit Co	ost	Number required	Tota	l cost
	Copper	Baseline		Copper	Baseline
Bed rails sets	€ 5,360	€ 4,020	20	€ 107,200	€ 80,400
Overbed tray table	€ 402	€ 201	20	€ 8,040	€ 4,020
Chair	€ 469	€ 335	20	€ 9,380	€ 6,700
Call button	€ 67	€ 27	20	€ 1,340	€ 540
Data device	€ 335	€ 134	20	€ 6,700	€ 2,680
IV pole	€ 402	€ 268	20	€ 8,040	€ 5,360
Optional copper items					
Grab rails					
Lever handle set					
Push plates set					
Cistern handle					
Tap set □					
Other 1					








Title Sheet

Inputs

Calculations

Results



York Health Economics Consortium

An Economic Evaluation of the Use of Copper in Reducing the Rate of Healthcare Associated Infections in the UK.

The purpose of this model is to calculate the number and associated costs of Healthcare Associated Infections in different clinical settings and to evaluate the benefits of a copper intervention on key touch surfaces compared to non-copper items. It then calculates the Return on Investment (ROI) and indicates other tangible benefits.

5 year results			
	Copper	Baseline	Incremental
Total cost (excluding cost of infections)*	€ 140,700	€ 99,700	€ 41,000
Number of infections	720	900	180
Cost per infection averted (excluding cost of in	€ 227.78		
Total QALYS gained	64.44		
Cost per QALY	€ 636.25		
Cost of infections*	.€ 1,080,000.00		
Total cost of intervention*	€ 4,460,700.00	€ 5,499,700.00	.€ 1,039,000.00
Cost per infection averted		<u> </u>	Dominant

^{*}These are direct costs to the hospital (no GP costs or societal costs have been included in the model)

Number of bed days saved per year	216
Cost per bed day day saved per year	€ 189.81

The number of bed days saved per year is 216, this would allow an increased capacity in the ICU by 38 beds with a typical length of stay of 5.7 days.

Return on investment < 3 months

The cost of the copper upgrade is €140,700 compared to €99,700 for installation of non-copper items. There were 720 infections in the copper group over the period and 900 in the baseline. This results in a cost per infection averted of €227.78.

These results are based on the following scenario:

 Number of beds per unit
 20

 Number of patients per year
 1,200

 Setting
 ICU

 Percentage reduction in infections
 20.0%

Type of infection All Healthcare Associated Infections



5 year results

•	Copper	Baseline	Incremental
Total cost (excluding cost of infections)*	€ 140,700	€ 99,700	€ 41,000
Number of infections	720	900	180
Cost per infection averted (excluding cost of in	€ 227.78		
Total QALYS gained	64.44		
Cost per QALY	€ 636.25		
Cost of infections*	.€ 1,080,000.00		
Total cost of intervention*	€ 4,460,700.00	€ 5,499,700.00	.€ 1,039,000.00
Cost per infection averted	Dominant		

^{*}These are direct costs to the hospital (no GP costs or societal costs have been included in the model)

Number of bed days saved per year	216		
Cost per bed day day saved per year	€ 189.81		

The number of bed days saved per year is 216, this would allow an increased capacity in the ICU by 38 beds with a typical length of stay of 5.7 days.

Return on investment	< 3 months

The cost of the copper upgrade is €140,700 compared to €99,700 for installation of non-copper items. There were 720 infections in the copper group over the period and 900 in the baseline. This results in a cost per infection averted of €227.78.

These results are based on the following scenario:

Number of beds per unit

Number of patients per year

Setting

Percentage reduction in infections

20

Number of patients per year

1,200

ICU

20.0%

Type of infection All Healthcare Associated Infections




factor	reference	example
HCAI rate in ICUs	25%	15%
reduction in HCAIs	58%	20%
pay back time		< 3 months
no of bed days saved per year		216
cost per bed day saved per year		€189.90



factor	reference	example 1	example 2
HCAI rate in ICUs	25%	15%	25%
reduction in HCAIs	58%	20%	20%
pay back time		< 3 months	< 1 month
no of bed days saved per year		216	360
cost per bed day saved per year		€189.90	€113.90







04.00 Conclusion & next steps

5 reasons to install Antimicrobial Copper touch surfaces

- 1. A supplement to standard hygiene practices
- 2. Continuous and significant bioburden reduction
- 3. Improved patient outcomes
- 4. A simple, cost-effective intervention
- 5. Payback in less than one year



The mark of the most effective antimicrobial touch surfaces



Cu⁺

The mark is licensed under a stewardship program run by the International Copper Association and its copper centres around the world. It is used by leading product manufacturers and copper fabricators to indicate that their products are made from Antimicrobial Copper. Why Antimicrobial Copper?

Scientific Proof

Markets and Applications Find Products and Partners News and Download Centre Supply Chain Resources

Antimicrobial Efficacy
How it Works
Public Health Claims
Clinical Trials
Laboratory Testing
EPA Registration
Research Groups
Scientific References





FAQs

▶ Book a meeting

Contact Centre

Scientific References

Proper Use and Care

Brochures, Presentations and Articles

▶ Request a call

"Nearly 300,000 people acquire Healthcare Associated Infections in the UK each year."

Taylor L, Plowman R and Roberts J A, A challenge of hospital-acquired infection, National Audit Office 2001

The Science behind Antimicrobial Copper

Science suggests that Antimicrobial Copper kills bacteria with a multifaceted attack

The mechanism by which Antimicrobial Copper kills bacteria is complex by nature, but the effect is simple. The questions and answers below summarise active and ongoing research seeking to explain how Antimicrobial Copper is the most effective touch surface.

How does copper affect bacteria?

Science suggests that copper surfaces affect bacteria in two sequential steps: the first step is a direct interaction between the surface and the bacterial outer membrane, causing the membrane to rupture. The second is related to the holes in the outer membrane, through which the cell loses vital nutrients and water, causing a general weakening of the cell.

How can copper punch holes in a bacterium?

Every cell's outer membrane, including that of a single cell organism like a bacterium, is characterised by a stable electrical micro-current. This is often called 'transmembrane potential', and is, literally, a voltage difference between the inside and the outside of a cell. It is strongly suspected that when a bacterium comes in contact with a copper surface, a short circuiting of the current in the cell membrane can occur. This weakens the membrane and creates holes.

Newsletter


Receive periodic emails covering breaking news, research findings, upcoming events and more...

Name:

Email:

Industry





What you can do

- take the message home: tell your executives & decision makers
- (tell the sales team)
- consider copper as a new opportunity during hospital new builds, ward or unit refurbishments
- visit anticrobialcopper.org for products and science



Keep in touch

- visit www.antimicrobialcopper.org
- sign up for newsletters (about 4 per year)
- visit us on stand B03 in Hall 14
- any feedback or questions can be sent to:

info@copperalliance.org.uk



Antimicrobial Copper

visit us on stand B03 in Hall 14

Thank you

Any questions?

Mark Tur, Technical Consultant, CDA

